This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

This quick guide contains an overview of the challenges associated with tobacco cessation and the benefits of being tobacco-free for individuals as well as those of a smoke-free workplace. It also includes tips that substance use disorder treatment settings can use to implement their own tobacco cessation programs.

This pamphlet offers reasons to combine tobacco cessation and substance use disorder treatment, including client testimonials and resources for implementing a tobacco cessation program. It also explains the benefits of offering tobacco cessation programs in substance use disorder treatment settings.

This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.